We kick off this week’s edition of the BioLines Weekender with a moving and meaningful video of “Magic” Max Schill, our 7-year old patient advocate, who continues to work toward the passage of the Senate’s version of the 21st Century Cures Act. Click here for Max’s video on why #CuresNow not tomorrow.
A number of new FDA drug approvals announced by New Jersey companies, including Braeburn Pharmaceuticals‘ Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence and Eli Lilly and Company’s Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) tablets for the treatment of type 2 diabetes (T2D) in adults.
Meanwhile, congrats to BioNJ Member Celator Pharmaceuticals for its acquisition by Jazz Pharmaceuticals. “The planned combination of Celator and Jazz is highly complementary, as both companies are dedicated to bringing differentiated therapies to patients who have high unmet medical needs,” said Scott Jackson, Chief Executive Officer of Celator. “We believe that Jazz Pharmaceuticals’ clinical and commercial expertise in hematology/oncology and existing international infrastructure will help realize the value of VYXEOS as a treatment to patients with AML.” A true New Jersey success story as well as inspiration for patients around the globe.
Congratulations to BioNJ Member ContraVir Pharmaceuticals, led by BioNJ Board Member James Sapirstein, on their acquisition of Ciclofilin Pharmaceuticals, enhancing Contravir’s presence in the hepatitis space.
Each year, the Research & Development Council of New Jersey honors the most exceptional efforts of scientists and inventors, along with their organizations, with the awarding of the prestigious Edison Patent Award. Click here to submit your patent and to learn more. Deadline is June 15.
Visit www.BioNJ.org to learn about the many upcoming events being hosted by BioNJ, including BioNJ’s Third Annual Diagnostics & Precision Medicine Summit on June 21 and our Inspiring Women in STEM Conference on June 28.
Click here to read this week’s Weekender.